| 4.31 -0.06 (-1.37%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.17  |
1-year : | 5.47 |
| Resists | First : | 4.43 |
Second : | 4.68 |
| Pivot price | 4.26 |
|||
| Supports | First : | 4.03 |
Second : | 3.35 |
| MAs | MA(5) : | 4.25 |
MA(20) : | 4.29  |
| MA(100) : | 4.24 |
MA(250) : | 3.68 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 59.5 |
D(3) : | 43.4 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 5.11 | Low : | 2.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PYPD ] has closed below upper band by 37.6%. Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.41 - 4.44 | 4.44 - 4.46 |
| Low: | 4.21 - 4.23 | 4.23 - 4.26 |
| Close: | 4.27 - 4.31 | 4.31 - 4.35 |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Fri, 10 Apr 2026
PYPD Options Volatility — NASDAQ:PYPD - TradingView — Track All Markets
Fri, 10 Apr 2026
PYPD Options Chain — NASDAQ:PYPD - TradingView — Track All Markets
Wed, 08 Apr 2026
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tue, 07 Apr 2026
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
Mon, 06 Apr 2026
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
Mon, 06 Apr 2026
PolyPid (PYPD) director details vested and future stock options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 21.3 (%) |
| Held by Institutions | 31.9 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -2.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.8 % |
| Return on Equity (ttm) | -366.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -2.07 |
| PEG Ratio | 0 |
| Price to Book value | 7.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|